tradingkey.logo

Nexalin Technology Inc

NXL
0.832USD
+0.026+3.29%
收盤 12/19, 16:00美東報價延遲15分鐘
15.13M總市值
虧損本益比TTM

Nexalin Technology Inc

0.832
+0.026+3.29%

關於 Nexalin Technology Inc 公司

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc簡介

公司代碼NXL
公司名稱Nexalin Technology Inc
上市日期Sep 16, 2022
CEOWhite (Mark)
員工數量6
證券類型Ordinary Share
年結日Sep 16
公司地址1776 Yorktown
城市HOUSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編77056
電話18322600222
網址https://nexalin.com
公司代碼NXL
上市日期Sep 16, 2022
CEOWhite (Mark)

Nexalin Technology Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+24.42%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+25.00%
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+24.42%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+25.00%

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%
地區USD
名稱
營收
佔比
International Sales
59.48K
84.26%
U.S. Sales
11.11K
15.74%
業務
地區
業務USD
名稱
營收
佔比
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
其他
86.15%
持股股東
持股股東
佔比
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
其他
86.15%
股東類型
持股股東
佔比
Individual Investor
13.78%
Investment Advisor
1.50%
Hedge Fund
1.11%
Investment Advisor/Hedge Fund
0.96%
Research Firm
0.16%
Venture Capital
0.06%
其他
82.44%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
37
1.33M
7.29%
+710.60K
2025Q2
41
2.88M
16.54%
-349.86K
2025Q1
40
2.89M
20.99%
-330.73K
2024Q4
39
2.84M
22.05%
+425.03K
2024Q3
30
2.89M
23.47%
+756.88K
2024Q2
27
1.82M
24.31%
-214.81K
2024Q1
20
1.77M
23.82%
-386.75K
2023Q4
19
1.75M
24.04%
-404.23K
2023Q3
19
1.79M
24.48%
+126.81K
2023Q2
18
1.72M
23.56%
+25.67K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Elson (Marilyn)
1.54M
8.7%
--
--
Jun 04, 2025
Hu (Benjamin)
377.10K
2.14%
+36.46K
+10.70%
Sep 29, 2025
White (Mark)
309.13K
1.75%
--
--
Jun 04, 2025
Owens (David)
185.75K
1.05%
+36.46K
+24.42%
Sep 29, 2025
The Vanguard Group, Inc.
159.88K
0.91%
--
--
Jun 30, 2025
MYDA Advisors LLC
800.00K
4.53%
+800.00K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
116.37K
0.66%
+2.30K
+2.01%
Jun 30, 2025
Kazden (Alan)
83.13K
0.47%
--
--
Jun 04, 2025
Renaissance Technologies LLC
46.34K
0.26%
+46.34K
--
Jun 30, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Nexalin Technology Inc的前五大股東是誰?

Nexalin Technology Inc的前五大股東如下:
Elson (Marilyn)
持有股份:1.54M
佔總股份比例:8.70%。
Hu (Benjamin)
持有股份:377.10K
佔總股份比例:2.14%。
White (Mark)
持有股份:309.13K
佔總股份比例:1.75%。
Owens (David)
持有股份:185.75K
佔總股份比例:1.05%。
The Vanguard Group, Inc.
持有股份:159.88K
佔總股份比例:0.91%。

Nexalin Technology Inc的前三大股東類型是什麼?

Nexalin Technology Inc 的前三大股東類型分別是:
Elson (Marilyn)
Hu (Benjamin)
White (Mark)

有多少機構持有Nexalin Technology Inc(NXL)的股份?

截至2025Q3,共有37家機構持有Nexalin Technology Inc的股份,合計持有的股份價值約為1.33M,占公司總股份的7.29% 。與2025Q2相比,機構持股有所增加,增幅為-9.24%。

哪個業務部門對Nexalin Technology Inc的收入貢獻最大?

在FY2025Q2,Equipment 業務部門對Nexalin Technology Inc的收入貢獻最大,創收52.53K,占總收入的74.41% 。
KeyAI